Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Division of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Cytotherapy. 2018 Mar;20(3):273-278. doi: 10.1016/j.jcyt.2018.01.009. Epub 2018 Feb 9.
The field of mesenchymal stromal cell (MSC) biology and clinical cellular therapy has grown exponentially over the last few decades. With discovery of multiple tissue specific sources of stromal cells, invariably being termed MSCs, and their increasing clinical application, there is a need to further delineate the true definition of a mesenchymal stromal cell and to recognise the inherit differences between cell sources; both their potential and limitations. In this review, we discuss the importance of considering every stromal cell source as an independent entity and the need to critically evaluate and appreciate the true phenotype of these cells and their safety when considering their use in novel cell therapies.
间质基质细胞(MSC)生物学和临床细胞治疗领域在过去几十年中呈指数级增长。随着多个组织特异性基质细胞来源的发现,通常被称为 MSC,以及它们在临床中的广泛应用,需要进一步明确间质基质细胞的真正定义,并认识到细胞来源之间的固有差异,包括它们的潜力和局限性。在这篇综述中,我们讨论了将每一种基质细胞来源视为独立实体的重要性,以及在考虑将这些细胞用于新型细胞治疗时,需要批判性地评估和欣赏这些细胞的真实表型及其安全性。